Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.

A Two Part Study to Assess Safety, PK, PD, and Food Effect of Oral HTL0016878

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03244228
Recruitment Status : Completed
First Posted : August 9, 2017
Last Update Posted : November 29, 2019
Sponsor:
Collaborator:
Allergan
Information provided by (Responsible Party):
Heptares Therapeutics Limited

Tracking Information
First Submitted Date  ICMJE August 3, 2017
First Posted Date  ICMJE August 9, 2017
Last Update Posted Date November 29, 2019
Actual Study Start Date  ICMJE August 25, 2017
Actual Primary Completion Date September 23, 2019   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: August 8, 2017)
  • Treatment emergent adverse events (TEAEs) [ Time Frame: Baseline up to 14 days post dose ]
    Safety and Tolerability
  • Physical examinations [ Time Frame: Baseline up to 14 days post dose ]
    Safety and Tolerability
  • vital signs (Heart Rate and Blood pressure) [ Time Frame: Baseline up to 14 days post dose ]
    Safety and Tolerability
  • Laboratory safety assessment [ Time Frame: Baseline up to 14 days post dose ]
    Safety and Tolerability
  • ECG [ Time Frame: Baseline up to 14 days post dose ]
    Safety and Tolerability
  • Columbia- suicide severity rating scale (C-SSRS) [ Time Frame: Baseline up to 14 days post dose ]
    Safety and Tolerability
Original Primary Outcome Measures  ICMJE Same as current
Change History Complete list of historical versions of study NCT03244228 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: August 8, 2017)
  • Maximum plasma concentration (Cmax) of HTL0016878 [ Time Frame: Baseline up to 14 days post dose ]
    Pharmacokinetics
  • Time to Maximum plasma concentration (Tmax) of HTL0016878 [ Time Frame: Baseline up to 14 days post dose ]
    Pharmacokinetics
  • Area under the curve of HTL0016878 [ Time Frame: Baseline up to 14 days post dose ]
    Pharmacokinetics
  • Half-life (t1/2) of HTL0016878 [ Time Frame: Baseline up to 14 days post dose ]
    Pharmacokinetics
  • Amount excreted in urine (Ae) of HTL0016878 [ Time Frame: Baseline up to 14 days post dose ]
    Pharmacokinetics
  • Fraction of dose eliminated unchanged on urine (fe/F) of HTL0016878 [ Time Frame: Baseline up to 14 days post dose ]
    Pharmacokinetics
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Two Part Study to Assess Safety, PK, PD, and Food Effect of Oral HTL0016878
Official Title  ICMJE A Two-part, Randomised, Double-blind, Placebo-controlled Single and Multiple Ascending Dose Study to Assess Safety, Pharmacokinetics and Pharmacodynamics of Oral HTL0016878 in Healthy Younger Adult and Elderly Subjects With a Randomised, Open-label, Crossover Arm to Assess the Effect of Food on Bioavailability of Oral HTL0016878.
Brief Summary Phase 1, first in human, two-part, single centre, placebo-controlled, single and multiple ascending dose trial in healthy younger and elderly adult subjects, with an open-label, randomised, crossover arms to assess the effect of food on bioavailability.
Detailed Description This is a first in human single and multiple ascending dose study with the objective to evaluate safety, tolerability, PK, PD, and food effect of HTL0016878 in healthy younger and elderly subjects. Part 1 will assess single doses of HTL0016878 and Part 2 will assess multiple doses of HTL0016878. Part 1 will be divided into 3 sub-parts: Part 1a will assess single ascending doses (SAD) of HTL0016878 in younger adult subjects, Part 1b will evaluate the effect of food on bioavailability of HTL0016878 and part 1c will investigate the effect of age on the PK of HTL0016878. Part 1c will only proceed after review of safety, tolerability and PK data from part 1a. Part 2 will be divided into 2 sub-parts to assess multiple ascending doses (MAD) of HTL0016878 in younger adult (part 2a) and elderly adult (part 2b) subjects. Part 2 will only proceed after review of safety, tolerability and PK data from Parts 1a, b and c.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:
Double blind
Primary Purpose: Treatment
Condition  ICMJE Healthy
Intervention  ICMJE
  • Drug: HTL0016878
    Oral solution
  • Drug: Placebo - Concentrate
    Matching placebo
Study Arms  ICMJE
  • Experimental: Part 1a SAD HTL0016878/Placebo
    In Part 1a, single ascending doses of HLT0016878 or matching placebo will be administered to groups of 12 subject each (9 active, 3 placebo). Each subject will have up to four treatment sessions separated by an appropriate wash-out. Healthy, young, male subjects.
    Interventions:
    • Drug: HTL0016878
    • Drug: Placebo - Concentrate
  • Experimental: Part 1b single dose HTL0016878
    In Part 1b, a single dose of HTL0016878 will be administered to 6 subjects on two occasions: once in the fasted and once the fed state. This will be open-label. Healthy, young, male or female subjects.
    Intervention: Drug: HTL0016878
  • Experimental: Part 1c single dose HTL0016878
    In Part 1c, a single dose of HTL0016878 will be administered to up to 6 (optional up to 12) healthy elderly subjects This will be open-label. Healthy, elderly, male subjects.
    Intervention: Drug: HTL0016878
  • Experimental: Part 2a MAD HTL0016878/Placebo
    In Part 2a, multiple doses of HTL0016878 will be administered to up to 5 cohorts (N=8, 6 active, 2 placebo) during one study session of 7 days. Healthy, young, male or female subjects.
    Interventions:
    • Drug: HTL0016878
    • Drug: Placebo - Concentrate
  • Experimental: Part 2b MAD HTL0016878/Placebo
    In Part 2b, multiple doses of HTL0016878 will be administered to up to 3 cohorts of healthy, elderly subjects (N=8, 6 active, 2 placebo) during one study session of 7 days. Healthy, young, male or female subjects.
    Interventions:
    • Drug: HTL0016878
    • Drug: Placebo - Concentrate
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: November 27, 2019)
120
Original Estimated Enrollment  ICMJE
 (submitted: August 8, 2017)
106
Actual Study Completion Date  ICMJE September 23, 2019
Actual Primary Completion Date September 23, 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Normotensive 18-55 year old (Parts 1a, 1b and 2a only) or 65+ year old (Parts 1c and 2b) male (all parts) or female (parts 1b, 2a and 2b only) volunteers with a body mass index 18-32kg/m².
  • Healthy on the basis of a clinical history, physical examination, electrocardiogram (ECG), vital signs, heart rate (part 1a only), exercise history (part 1a only), and laboratory tests of blood and urine.
  • Willingness to comply with requirements or the trial, including contraception requirements.
  • Able to give fully informed consent.

Exclusion Criteria:

  • Positive tests for hepatitis B & C, HIV
  • severe adverse reaction to any drug
  • sensitivity to trial medication
  • drug or alcohol abuse
  • smoking
  • use of medication that inhibits CYP2D6 within previous 21 days or other prescribed and over-the-counter medication and herbal remedies within previous 21 days before dosing (with the exception of acetaminophen, contraceptive medications and hormone replacement therapy), unless the principal investigator (PI) considers that it would not interfere with trial
  • participation in other clinical trials of unlicensed medicines in the previous 3 months, or regularly take part in more than 4 studies a year
  • loss of more than 500 mL blood in the previous 3 months
  • vital signs, QTcF interval or laboratory values outside the acceptable range
  • poor metabolizers of CYP2D6 (apart from one optional cohort in Part 1a, which may enrol poor metabolizers only)
  • clinically relevant abnormal findings at the screening assessment
  • acute or chronic illness
  • history of epilepsy or seizures
  • clinically relevant abnormal medical history or concurrent medical condition
  • disease associated with cognitive impairment and/or psychosis
  • recent history of suicidal thoughts or ideation, or insomnia
  • excessive use of caffeine containing beverages, exceeding 8 cups of coffee or equivalent/day and the inability to refrain from the use of caffeine containing beverages whilst on the ward
  • consumption of cranberry, pomegranate, star fruit, grapefruit, pomelos, exotic citrus fruits or Seville oranges (including marmalade and juices made from these fruits) within 3 days before admission; possibility that volunteer will not cooperate
  • pre-menopausal females who are pregnant or lactating, or who are sexually active and not using a reliable method of contraception
  • Objection by the GP.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE Child, Adult, Older Adult
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United Kingdom
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03244228
Other Study ID Numbers  ICMJE HTL0016878-101
2017-001385-26 ( EudraCT Number )
16-028 ( Other Identifier: HMR )
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Heptares Therapeutics Limited
Study Sponsor  ICMJE Heptares Therapeutics Limited
Collaborators  ICMJE Allergan
Investigators  ICMJE Not Provided
PRS Account Heptares Therapeutics Limited
Verification Date November 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP